Trial Profile
A Randomized, Open-Label, Prospective Study Evaluating the Safety and Effectiveness of Elbasvir, Grazoprevir with or without Ribavirin alongwith its Effectiveness with Sofosbuvir in Chronic Hepatitis C (Genotype 1) Prior Experienced HIV Co-Infected Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2017
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms EGRESS-C
- 13 Nov 2017 New trial record
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases